EvoGenix clears second hurdle in GSK pact
EvoGenix is touting the launch of its second project with GlaxoSmithKline as clear validation of its drug development know-how. The Australian biotech is helping Glaxo develop antibodies. "EvoGenix is employing its protein engineering technologies in developing a series of protein therapeutics with a particular focus on antibody-based drugs," the company said. EvoGenix earns research funds and new milestones as it progresses in its deal to collaborate on up to three different projects.
- check out the release
- here's the report from The Age
Related Article:
Peptech buys EvoGenix in $156M antibody deal. Report
New study highlights risks of anti-TNF antibody class. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
